Ovarian Cancer Clinical Trial
Official title:
Access to Fast Transvaginal Ultrasound Through General Practice for Earlier Diagnosis of Ovarian Cancer
NCT number | NCT03069872 |
Other study ID # | 210278 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 5, 2017 |
Est. completion date | April 30, 2018 |
Verified date | April 2018 |
Source | University of Aarhus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background
Ovarian cancer (OC) is a disease with a poor prognosis due to diagnosis at late stage.
Early-stage OC presents with non-specific and vague symptoms and therefore OC usually is not
detected until reaching an advanced stage. From 2008, Danish general practitioners (GPs)
could urgently refer patients suspected of having OC to standardized cancer patient pathways
(CPPs). The CPP is designed for women presenting specific signs and alarm symptoms, and is
supposed to shorten the pathway from suspicion to treatment.
Hypothesis
Direct access to fast transvaginal ultrasound (TVU) through general practice is feasible in
earlier diagnosis of OC.
Aim
The aim of this study is to assess the implementation and clinical implications of direct
referral access to fast TVU through general practice.
Materials and methods
The study is a feasibility study and GPs from in Central Denmark Region are offered direct
access to fast TVU for women aged 40 years or more who present symptoms that could origin
from OC, but which are not classified as alarm symptoms. The GPs will receive education about
updated knowledge on OC symptoms and the use of the guideline for earlier diagnosis of OC in
general practice. The study period is 1 year.
Perspectives
There is a great need to test rational strategies for diagnosing OC at an earlier stage in
order to improve survival. For women who do not fulfil access criteria for the CPP, and for
whom the main prospect for earlier diagnosis is improved identification of symptomatic OC,
this study may provide important new knowledge of how to facilitate the diagnostics of OC in
the future and reduce time to diagnosis and improve survival.
Status | Completed |
Enrollment | 490 |
Est. completion date | April 30, 2018 |
Est. primary completion date | April 30, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - GPs in the Central Denmark Region - Women =40 years presenting with vague and non-specific symptoms Exclusion Criteria: - Women who fulfil access criteria for OC fast-track referral. |
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University | Aarhus | Region Midt |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of TVU use | TVU will be requested electronically through an online referral-system used by Danish GPs. This outcome will be evaluated descriptively by illustrating the relation between time and use of TVU. |
one year | |
Primary | Action taken on test results | After all TVU investigations, a discharge summary will be send electronically to the referring GP. If indicated, instructions for follow-up investigations is stated in the discharge summary. To evaluate if GPs follow these instructions, data on discharge summary recommended follow-up are compared to data on follow-up referrals made by the GPs. This outcome will be evaluated descriptively. |
one year | |
Primary | Patient-reported symptoms before TVU investigation | All women who are referred to TVU will receive a questionnaire prior to investigation, regarding experienced symptoms during the past year. | one year | |
Primary | Indication for fast TVU | GPs refer women to TVU electronically. Information about indications for the investigation, is required in the referral. These informations will be used to evaluate the GPs reasons for referring the women to TVU and will be evaluated descriptively. | one year | |
Secondary | Findings by TVU on women with vague and non-specific symptoms | An overview of all findings by TVU will be provided, and possible side effects will be assessed. An algorithm for the use of TVU has been developed, and the principal investigator will tick a box specifying what has been discovered during the investigation. Findings by TVU is identified in the algorithm used for TVU and by ICD-10 codes. |
one year | |
Secondary | Ovarian Cancer (OC) stage distribution | Number of OC diagnosed in each cancer stage (FIGO I-IV) | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |